Skip to main content
Caplight Logo









Thymmune Therapeutics

Thymmune Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.thymmune.com/

Last Round

Grant

Sep 29, 2023

Total Funding Raised

$52M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Thymmune Therapeutics is a biotechnology company developing a proprietary T-Lymune™ platform to restore and enhance the function of the thymus to address a wide range of immune-related disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, ML Platforms

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Application

Keywords

thymus regenerationcell therapyiPSC-derived cell therapyoff-the-shelf cell therapyinduced pluripotent stem cellsiPSCsthymic engineeringimmune restorationregenerative medicinemachine learning platformcell therapy manufacturingimmunodeficiency disordersautoimmune disordersARPA-Hlongevity biotechcongenital athymia

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Thymmune Therapeutics Comparables

Compare Thymmune Therapeutics with similar companies based on industry and business-model similarity.

Thymmune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tolerance Bio, Inc.
86%
TECregen
78%
Stratus Therapeutics
75%

Thymmune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 29, 2023
SeedMar 1, 2023
GrantFeb 1, 2023

Key People

Founding team and executive leadership

Bing Lim

Co-Chief Executive Officer

Executive Team

Stan Wang

CEO & Founder

Founding Team

Thymmune Therapeutics Investors

Notable investors and investment history

Thymmune Therapeutics investors
InvestorRounds
National Institute of Allergy and Infectious DiseasesGrant
Pags GroupSeed
Pillar VCSeed
ARPA-HGrant
NYBC VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 16, 2026

    Open roles increased to 11, 39% of headcount.

  • Feb 2, 2026

    Monthly visitors grew 64% MoM.

Thymmune Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Thymmune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Thymmune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range25
Year Founded2021
Last FundingSep 29, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?